Heart Transplantation
Allotrap peptide RDP58 inhibits aortic graft arteriosclerosis
Published in Cardiovascular Week, January 12th, 2004
According to published research from the United States, "There remains no treatment for chronic allograft rejection mainly manifested by progressive arteriosclerosis."
W. Li and coauthors at the University of Pittsburgh "investigated the effect of Allotrap peptide RDP58 therapy on arteriosclerosis in an aortic allotransplant model."
"RDP58 was administered intraperitoneally at 0.1, 0.5, or 2.5 mg/kg, every other day after transplantation," they explained. Test results showed that "RDP58 therapy markedly inhibited vascular intimal thickening, media...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
Source: Cardiovascular Week (2004-01-12)
More Articles from Cardiovascular Week
- Arrhythmias
Twenty-seven new, life-threatening cardiac events reported by Atkins-type dieters - Antithrombin Deficiency
Enrollment complete in European efficacy study for rhATIII - Atherosclerosis
DHEA increases macrophage foam-cell formation - Atherosclerosis
Incidence of coronary atherosclerosis in type 2 diabetes increased - Atrial Flutter
U.S. pivotal trial begins for cardiac cryoblation system - Cardiac Arrest
Sudden-death risk tracked in large, long-running study of young athletes - More from this issue of Cardiovascular Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
